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Primary coenzyme Q10 deﬁciency-7: expanded phenotypic
spectrum and a founder mutation in southern Chinese
Mullin Ho-Chung Yu 1, Mandy Ho-Yin Tsang1, Sophie Lai1, Matthew Sai-Pong Ho1, Donald M. L. Tse2, Brooke Willis1,
Anna Ka-Yee Kwong1, Yen-Yin Chou3, Shuan-Pei Lin4, Catarina M Quinzii5, Wuh-Liang Hwu6, Yin-Hsiu Chien 6, Pao-Lin Kuo7,
Victor Chi-Man Chan8, Cheung Tsoi9, Shuk-Ching Chong10, Richard J. T. Rodenburg11, Jan Smeitink11, Christopher Chun-Yu Mak 1,
Kit-San Yeung1, Jasmine Lee-Fong Fung1, Wendy Lam2, Joannie Hui12, Ni-Chung Lee6, Cheuk‐Wing Fung1 and Brian Hon-Yin Chung 1
Primary coenzyme Q10 deﬁciency-7 (COQ10D7) is a rare mitochondrial disease caused by biallelic mutations in COQ4. Here we
report the largest cohort of COQ10D7 to date, with 11 southern Chinese patients conﬁrmed with biallelic COQ4 mutations. Five of
them have the classical neonatal-onset encephalo-cardiomyopathy, while the others have infantile onset with more heterogeneous
clinical presentations. We also identify a founder mutation COQ4 (NM_016035.5): c.370G>A, p.(Gly124Ser) for COQ10D7, suggesting
a higher chance of occurrence in the southern Chinese. This study helps improve understanding of the clinical spectrum of this
disorder.
npj Genomic Medicine            (2019) 4:18 ; https://doi.org/10.1038/s41525-019-0091-x
INTRODUCTION
Coenzyme Q10 (CoQ), also known as ubiquinone, is crucial for the
function of mitochondrial respiratory chain complexes. Currently,
the pathway of CoQ biosynthesis is known to involve at least 18
proteins. Primary CoQ deﬁciencies in humans involve genetic
mutations in COQ2, PDSS1, PDSS2, COQ8A, COQ9, COQ6, COQ4, or
COQ7.1
The primary CoQ10 deﬁciency-7 (COQ10D7, MIM: 616276) is
caused by autosomal-recessive mutations in COQ4. COQ4 is
hypothesized to take part in stabilizing the CoQ complex.2 To
date, biallelic COQ4 mutations have been described in 16 patients
from 11 unrelated families. They were reported in two case series
(with ﬁve to six cases each) and three case reports. The patients
described had common features of cardiomyopathy, encephalo-
pathy, lactic acidosis often with a neonatal onset, and death in the
neonatal or infantile period.2–4 Two siblings of childhood onset
presenting with spinocerebellar ataxia and stroke-like episodes5
and two Chinese siblings with neonatal onset of dystonia, seizures,
lactic acidosis, and cerebellar atrophy were described in recent
case reports.6
In this report, we have 11 patients (4 males and 7 females) from
9 unrelated families who were managed by the Medical Genetics
division of the Department of Paediatrics and Adolescent
Medicine at the University of Hong Kong and the Department of
Medical Genetics and Pediatrics at the National Taiwan University
Hospital in the period of 2014–2018. They presented with two
overlapping phenotypes: the classical neonatal-onset encephalo-
cardiomyopathy and infantile-onset encephalopathy with or
without cardiomyopathy. They were diagnosed as COQ10D7 due
to homozygous or compound heterozygous COQ4 mutations. All
genetic diagnoses were made by whole-exome sequencing (WES)
except Patient 4, Patient 5, and Patient 11 due to their known
family history and recognizable features of COQ10D7. More
importantly, we have identiﬁed a Chinese-speciﬁc COQ4 founder
mutation in 10 subjects, 5 of whom are homozygous for that
mutation.
CASE REPORTS
The study was approved by the institutional review board of the
University of Hong Kong/Hospital Authority Hong Kong West
Cluster (UW12-211) and the National Taiwan University Hospital
(201703073RINB). Written informed consent was obtained from
subjects or their parents. A summary of the clinical, biochemical,
and radiological characteristics of the 11 patients with COQ4
mutations identiﬁed is presented in Table 1. Patients 1–5 had the
classical neonatal-onset phenotype described by Brea-Calvo et al.
and Chung et al.,2,3 whereas Patients 6–11 had later onset and
more heterogeneous features. The frequency of distinct pheno-
types compared with previous studies is summarized in Table 2.
The corresponding MRI (magnetic resonance imaging) images are
presented in Fig. 1. The pedigrees of the nine families are
presented in Fig. 2.
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Patient 1
Patient 1 was a male with an antenatal history of oligohydramnios
and intrauterine growth restriction (IUGR). He was born at
38 weeks. At 7 days old, he developed recurrent episodes of
apnea, decreased activity, and mild lactic acidemia. On day 14, he
developed circulatory collapse with severe metabolic acidosis and
lactic acidosis up to 28.36 mmol/L (reference range 0.5–2.20),
hypotension requiring multiple inotropes, an episode of pulseless
ventricular tachycardia, and respiratory failure requiring intubation
and ventilator support. Thereafter, he developed recurrent
convulsions controlled by phenobarbitone and levetiracetam.
MRI of the brain at 3 weeks of age showed symmetrical T1 and T2
hyperintensity with restricted diffusion at bilateral lentiform
nuclei. Foci of restricted diffusion were also detected at bilateral
frontal white matter (Fig. 1a–c). Magnetic resonance spectroscopy
(MRS) showed raised lactate peaks at bilateral basal ganglia and
cerebral white matter. Subsequent follow-up MRI showed
established infarcts with cystic changes at bilateral lentiform
nuclei (Fig. 1d). Mild cerebellar hypoplasia was also noted. Serial
echocardiography in the following months showed progressive
septal and ventricular myocardial hypertrophy. WES identiﬁed
compound heterozygous mutations in COQ4, a missense
c.370G>A, p.(Gly124Ser) and a splicing mutation c.402+1G>C.
Functional analysis of the skin ﬁbroblasts showed ETC complex II
+III deﬁciency due to low CoQ concentration. At 5 months of age,
CoQ10 supplement up to 40mg/kg/day. At 8 months, in view of
poor neurological prognosis and poor response to CoQ10
treatment, he was diverted to comfort care and extubated. He
passed away shortly from respiratory failure.
Patient 2
Patient 2 was a term newborn male. He developed respiratory
distress, hypotension, and progressive metabolic acidosis with a
lactate level of 2.6 mmol/L and hyperalaninemia requiring
intubation and inotropic support on day 1 of life. Echocardiogram
revealed hypertrophic cardiomyopathy. Plasma amino acids
revealed high alanine, proline, and tyrosine, and acylcarnitine
proﬁle was unremarkable. CoQ10 supplement at 15 mg/kg/day
and carnitine at 100mg/kg/day were tried on his second day of
life but the patient succumbed. WES revealed compound
heterozygous mutations in COQ4: a missense c.370G>A, p.
(Gly124Ser) and a splicing mutation of c.402+1G>C.
Patient 3
Patient 3 was born full term at 37 weeks. She developed transient
respiratory distress shortly after birth. On day 22 of life, she had
cardiogenic shock. Echocardiogram showed poor contractility with
a left ventricular ejection fraction of 20% and a moderate
pericardial effusion. There was associated lactic acidemia
(24 mmol/L; reference range 0.5–2.2) and hyperammonemia
(139 µmol/L; reference range <100). She was empirically given
CoQ10 supplementation and intravenous immunoglobulin. Her
cardiac function improved gradually and normalized by day 32 of
life. She developed seizures at 4 months of age requiring multiple
anticonvulsants. She is severely delayed developmentally. WES
revealed a homozygous COQ4 mutation c.370G>A, p.(Gly124Ser).
Patient 4 and Patient 5
Patient 4 was the younger sister of Patient 5. She had antenatal
history of IUGR and was born at 38 weeks. Immediately postnatal,
she developed respiratory distress with intermittent apnea and
lactic acidemia (up to 10mmol/L; reference range 0.5–2.2). MRI
brain showed symmetrical T1 hyperintensity at bilateral basal
ganglia, with mild cerebellar hypoplasia (Fig. 1e). MRS showed
raised lactate peaks at bilateral basal ganglia (Fig. 1f). She
developed treatment-resistant seizures at 2 months of age.
Subsequent MRI at 9 months of age showed generalized
progressive cerebellar and cerebral atrophy, with diffuse white
matter loss including thinning of the corpus callosum. Cystic
changes were seen within the cerebral white matter, bilateral
basal ganglia, and thalami (Fig. 1g). Serial echocardiogram showed
progressive moderate left ventricular hypertrophy. Owing to the
recognizable clinical presentation, Sanger sequencing was per-
formed and revealed compound heterozygous COQ4 mutation:
c.370G>A, p.(Gly124Ser) and c.402+1G>C. CoQ10 supplement has
been started since age of 4 years 5 months.
Patient 5 was the elder sister of Patient 4. She was born at
39 weeks with an antenatal history of IUGR. She developed
seizures from 2 months of age with associated lactic acidosis and
respiratory failure requiring home ventilation. Chest radiograph
showed cardiomegaly. CoQ10 supplementation was tried at 1 year
of age but passed way from respiratory failure 1 month after. After
the genetic diagnosis of her younger sister, Sanger sequencing
was performed retrospectively and revealed the same compound
heterozygous COQ4 mutation as her sister, c.370G>A, p.(Gly124-
Ser) and c.402+1G>C.
Table 2. Phenotypic comparison between patients in this study and previously reported cases
This study Chung et al.3 Brea-Calvo et al.2 Sondheimer et al.4 Bosch et al.5 Lu et al.6
Number of subjects 11 6 5 1 2 2
Female-to-male ratio 7:4 6:0 3:2 0:1 1:1 1:1
Age of presentation Birth to 8 months Birth to day 1 Birth to 6 h 1 day 4–9 years 1–2 months
Neonatal onset 5/11 (45%) 6/6 (100%) 4/5 (80%) 1/1 (100%) 0/2 (0%) 2/2 (100%)
Infantile onset 6/11 (54%) 0/6 (0%) 1/5 (20%) 0/1 (0%) 0/2 (0%) 0/2 (0%)
Childhood onset 0/11 (0%) 0/6 (0%) 0/5 (0%) 0/1 (0%) 2/2 (100%) 0/2 (0%)
Respiratory distress 5/11 (45%) 6/6 (100%) a4/4 (100%) 1/1 (100%) — 2/2 (100%)
Cardiomyopathy 6/11 (54%) 5/6 (83%) 2/5 (40%) 1/1 (100%) — 1/2 (50%)
Hypotonia 7/11 (64%) a5/5 (100%) 2/5 (40%) 1/1 (100%) — —
Dystonia 2/11 (18%) — — — — 2/2 (100%)
Seizures 8/11 (73%) 3/6 (50%) 3/5 (60%) 1/1 (100%) 2/2 (100%) 2/2 (100%)
Lactic acidosis 10/11 (91%) 4/6 (67%) 4/5 (80%) 1/1 (100%) — 2/2 (100%)
Cerebellar atrophy 6/11 (54%) a4/5 (80%) 3/5 (60%) — — 2/2 (100%)
Basal ganglia 5/11 (45%) — — — — 1/2 (50%)
aLacking information from one patient
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Patient 6
Patient 6 presented at 8 months of life with severe global
developmental delay, microcephaly, generalized dystonia, cortical
visual impairment, and oromotor dysfunction. Metabolic workup
revealed lactic acidemia of 2.5–5.9 mmol/L and hyperalanemia
(626 µmol/L; reference range 143–439). WES revealed compound
heterozygous mutations in the COQ4 gene: c.550T>C, p.
(Trp184Arg) and c.402+1G>A. Functional analysis of the skin
ﬁbroblasts showed ETC complex II+III deﬁciency with low CoQ
concentration. There was no further follow-up because of overseas
adoption.
Patient 7
Patient 7 was a girl, born full term. She had bilateral cortical visual
impairment since birth and progressive oromotor dysfunction
requiring gastrostomy feeding. She had severe global develop-
mental delay. She developed generalized dystonia and spasticity
around 5 months of age. Lactic acidemia of 2.4–3.2 mmol/L was
present. WES revealed a homozygous variant in the COQ4 gene:
c.370G>A, p.(Gly124Ser). Functional analysis of the skin ﬁbroblast
showed ETC complex II+III deﬁciency and low CoQ concentration.
She had been on CoQ10 supplement since 2 years old. There was
no clinical improvement and the patient died at 3 years and
6 months of age.
Patient 8
Patient 8 is a girl, born full term. She developed infantile spasms at
6 months of age. Metabolic workup showed lactic acidemia at
2.2–4.2 mmol/L and hyperalanemia (487 µmol/L; reference range
143–439). WES revealed compound heterozygous variants of the
COQ4 gene c.371G>T, p.(Gly124Val) inherited from the mother
and c.370G>A, p.(Gly124Ser) inherited from the father. Interest-
ingly, respiratory chain enzymology of the skeletal muscle
activities was normal but skin ﬁbroblast functional analysis
showed ETC complex II+III deﬁciency and low CoQ10 concentra-
tion. CoQ10 supplement has been given since 9 months of age,
Fig. 1 Cerebral magnetic resonance (MR) ﬁndings. a Axial T1W, b axial FLAIR, c DWI from Patient 1 at neonatal stage, and d axial T2W at
follow-up; e axial T1W and fMR spectroscopy (MRS) at basal ganglia at neonate and g axial T1W at infant stages from Patient 4; h coronal T2W,
i sagittal T1W, j axial T2W, k axial T1W from Patient 11. MR features include cerebellar atrophy (white arrows) (h, i) with progression (e, g);
cerebral atrophy with frontal and anterior temporal lobar predominance (i–k); thinning of the corpus callosum (i); white matter loss and cystic
change with frontal predominance (asterisks) (j, k); basal ganglia involvement with restricted diffusion and cystic change on follow-up (curved
arrows) (a–d); lactate peak at around 1.3 ppm on MRS (arrowheads) (f)
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with subjective improvement in responsiveness. She is alive and
has achieved fair seizure control with levetiracetam and global
developmental delay.
Patient 9
Patient 9 is a boy, born full term at 40 weeks. He presented with
infantile spasms at 2 months of age. CoQ10 supplementation
started at 7 years of age and has remained stable. WES revealed a
homozygous COQ4 mutation, c.370G>A, p.(Gly124Ser). Skin
ﬁbroblast functional analysis showed ETC complex II+III deﬁciency
and low CoQ concentration.
Patient 10 and Patient 11
Patient 10 is the younger sister of Patient 11. She was born at
36 weeks. She developed transient respiratory distress after birth.
She was asymptomatic until 2 months of age when she developed
progressive hypotonia, cortical visual impairment, severe devel-
opmental delay, and seizures requiring multiple anticonvulsants.
Her echocardiogram showed progressive dilated cardiomyopathy
Fig. 2 Pedigrees of 9 families with 11 subjects described in our study
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and mitral regurgitation. WES revealed a homozygous COQ4
mutation: c.370G>A, p. (Gly124Ser). CoQ10 supplement at 30 mg/
kg/day was started at 11 months of age, and her seizure control
improved.
Patient 11 is the elder sister of Patient 10. She was born full
term. At 4 months of age, she presented with seizures, hypotonia,
spasticity, oromotor dysfunction, and severe developmental delay.
She also developed an episode of acute myocarditis during which
her echocardiogram showed diastolic dysfunction. Brain MRI at
14 months showed mild cerebellar atrophy and cerebral atrophy,
white matter cystic changes with bilateral frontal and anterior
temporal predominance, and thinning of the corpus callosum.
Basal ganglia and brainstem appeared preserved (Fig. 1h–k). No
lactic acidosis was detected. Owing to the exome ﬁndings of her
sister, Sanger sequencing was performed and revealed a
homozygous COQ4 mutation: c.370G>A, p.(Gly124Ser). She was
not on CoQ10 supplement and passed away at 20 months due to
an episode of sepsis.
RESULTS
Pathogenicity of the COQ4 variants
We analyzed the COQ4 variants identiﬁed in our cohort by
previously reported literatures, ClinVar, population frequency in
gnomAD,7 conversation score by Combined Annotation-
Dependent Depletion,8 in silico prediction by Rare Exome Variant
Ensemble Learner,9 and protein stability change prediction by
STRUM10 (Table 3). All variants demonstrated a deleterious effect.
Together with the reduced level of CoQ10 of the patients, the
pathogenicity of these variants is strongly supported by the
biochemical ﬁndings of the patients.
Founder mutation analysis
Among these 11 patients, we identiﬁed the same missense
mutation c.370G>A, p.(Gly124Ser) in 10 of them. This missense
mutation is a rare variant with a population frequency of 0.001118
and it is exclusively found in South East Asians in the gnomAD
database.7 Further analysis of the DNA of the ﬁve homozygous
patients using Inﬁnium OmniZhongHua-8 BeadChip SNP array
showed a common haplotype of 0.464–3.290 cM implying that the
mutation was inherited from a common ancestor 27 generations
ago (Fig. 3). In addition, by principal component analysis), our SNP
array data are clustered with Chinese and Japanese of HapMap
Phase II (n= 270) and a local southern Chinese database (n= 612).
Furthermore, the pathogenicity of this mutation has been
established via the reduced CoQ level in the skin ﬁbroblasts in
Patients 7 and 9 who have homozygous c.370G>A mutation (Table
4). Altogether our study conﬁrms that the missense mutation
c.370G>A, p.(Gly124Ser) represents a pathogenic founder muta-
tion in the southern Chinese population.
DISCUSSION
To our knowledge, this is the largest case series of primary
COQ10D7 reported. In the literature, primary COQ10D7 cases have
been described predominantly with a neonatal onset, with only
two cases of childhood onset.2–5,8 In this study, we have expanded
the phenotypic spectrum of primary COQ10D7 from neonatal to
infantile onset.
We have ﬁve patients exhibiting the well-described neonatal
presentation of COQ10D7 as in the literature, characterized by
respiratory distress, encephalopathy, seizures, hypotonia, and
cardiomyopathy. Previously, it was believed that phenotypes from
affected males with COQ4 mutation would be more severe and
highly likely lethal.3,6 However, in our study the male-to-female
death ratio was 2:3.
We have six patients with infantile-onset phenotypes. Unlike
those of neonatal onset, MRI brain for those infantile-onset
patients did not show characteristic basal ganglia lesions. Dystonia
was observed in two out of the six patients with infantile-onset
presentation in our cohort, and it was also observed in the two
neonatal-onset cases reported by Lu et al.8 but not reported in
non-Chinese patient.
A summary of the predominant phenotypes in the spectrum of
neonatal, infantile, and childhood onset of COQ10D7 is shown in
Fig. 4. The variegated symptoms and disease onsets explain the
frequent delay of diagnoses of COQ10D7. This also highlights the
importance of the complementarity of biochemical screening for
children with unexplained neurological disturbances and the
prompt application of WES in order to reach a genetic diagnosis
that has an impact on patient management.
Functional analysis to demonstrate the deﬁciency of CoQ
should be carefully examined because mitochondrial enzymology
can be tissue speciﬁc. In this study, among the ﬁve patients
(Patients 1, 6, 7, 8, 9) with ETC chain analysis in the skin ﬁbroblast,
all of them shown a reduced level of succinate:cytochrome c
oxidoreductase (complex II+III). Measurement of CoQ level was
also found signiﬁcantly decreased. For Patients 7 and 8, complex II
+III analysis and CoQ level measurement were also performed in
the muscle. Interestingly, the CoQ level from the muscle is normal
but that from skin ﬁbroblasts was reduced. From the Genotype-
Tissue Expression (GTex) data, the COQ4 median expression in the
muscle is 7.58 transcripts per million (TPM) while in the skin it is
44.14 TPM, demonstrating a 6-fold lower expression in the muscle.
Table 3. Analysis of the four variants identiﬁed in our cohort
Variant gnomAD population frequency Reported to be disease causing? CADD REVEL ddG
c.370G>A, p.(Gly124Ser) 1.13e−04 Yes (Lu et al.6) 24.8 0.817 −1.19
c.402+1G>C 2.79e−05 Yes (ClinVar) 28.8 N/A N/A
c.371G>T, p.(Gly124Val) 3.98e−06 No 24.6 0.753 −1.53
c.550T>C, p.(Trp184Arg) 0 No 26.7 0.538 −0.62
CADD Combined Annotation-Dependent Depletion, REVEL Rare Exome Variant Ensemble Learner, N/A not available
Fig. 3 Founder mutation analysis. Shared haplotypes among
homozygous COQ4:c.370G>A. Red square indicates the location of
homozygous COQ4:c.370G>A, while black square indicates the
nearest heterozygous single-nucleotide polymorphism. The length
of the haplotype for each subject is at the right panel. The maximum
shared length is approximately 577 kb
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More signiﬁcantly, we have identiﬁed a common founder
pathogenic COQ4 mutation associated with COD10D7. In this
study, 10 out of the 11 patients carry the COQ4: c.370G>A, p.
(Gly124Ser) allele. This mutation fulﬁlls the criteria of a founder
mutation: (1) all patients with the mutant alleles share a haplotype
associated with the mutation; (2) the haplotype is shared among
affected families with a genetic distance >1 cM; (3) the mutant
allele is rare and speciﬁc to the population; and (4) all carriers are
delineated to the same geographic region. It is likely that this
founder mutation causes a relatively higher rate of COQ10D7 in
southern Chinese individuals, and that may explain why we can
present a larger cohort as compared to past studies in this ﬁeld.
CoQ10 oral supplementation was previously reported effective
in COQ4 mutation cases.2–4,6
Among the 10 patients who received CoQ10 supplement and
with continuous follow-up, those shown with stabilized cardiac
condition or seizure control are those of genotype of homozygous
missense variant c.370G>A (Patients 3, 9, 10). Another patient on
CoQ supplement with improved clinical condition is Patient 8 with
genotype of compound heterozygous missense variants
c.370G>A/c.371G>T. For those without improvement are patients
with genotype in the presence of a splicing mutation c.402+1G>A
(Patients 1, 2, 4, 5, 6). Among these ﬁve patients, three of them
(Patients 1, 2, and 5) died from the disease. Retrospectively,
Patients 1, 4, and 5 were documented IUGR antenatally. This may
suggest that the presence of c.402+1G>A, a loss-of-function
mutation, would cause more severe neonatal onset of phenotypes
and less responsive to CoQ10 supplement.
In this study, we have expanded the phenotypic spectrum of
COQ4 mutation. Now COQ10D7 can range from neonatal, infantile
to childhood onset. We have also identiﬁed a pathogenic COQ4
founder mutation in the southern Chinese population. The
importance of complementarity of biochemical screening and
prompt application of WES on patients with unexplained
neurological symptoms is highlighted.
Reporting summary
Further information on experimental design is available in the
Nature Research Reporting Summary linked to this paper.Ta
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Fig. 4 Phenotypic spectrum of neonatal, infantile, and childhood
onset of COQ10D7 from all the reported cases including this study.
†Lactic acidosis is not mentioned in the childhood-onset cases. (The
color intensity representing the percentage of patients having that
clinical presentation in arbitrary form)
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